Page last updated: 2024-10-15

immucillin g

Description

immucillin G: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135445969
CHEMBL ID473922
CHEBI ID43467
SCHEMBL ID505709
MeSH IDM0292229

Synonyms (20)

Synonym
1,4-dideoxy-1,4-imino-1-(s)-(9-deazaguanin-9-yl)-d-ribitol
immucillin-g
DB02230
(1s)-1,4-dideoxy-1,4-imino-1-(9-deazaguanin-9-yl)-d-ribitol
CHEBI:43467 ,
immucillin g
2-amino-7-[(2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,5-dihydro-4h-pyrrolo[3,2-d]pyrimidin-4-one
CHEMBL473922 ,
bdbm50293086
SCHEMBL505709
2-amino-7-[(2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3,5-dihydro-4h-pyrrolo[3,2-d]pyrimidin-4-one
(1s)-1-c-(2-amino-4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-dideoxy-1,4-imino-d-ribitol
HBOWYTRRSFMYRU-PVEDRDFWSA-N
Q27120518
2-amino-7-((2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl)-1h-pyrrolo[3,2-d]pyrimidin-4(5h)-one
209799-75-7
4h-pyrrolo(3,2-d)pyrimidin-4-one, 2-amino-7-((2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl)-3,5-dihydro-
unii-xlm0q9h891
2-amino-7-((2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl)-3,5-dihydro-4h-pyrrolo(3,2-d)pyrimidin-4-one
xlm0q9h891 ,
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
pyrrolopyrimidine
dihydroxypyrrolidine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Purine nucleoside phosphorylaseHomo sapiens (human)Ki0.00490.00000.52897.0000AID1571176; AID1578784; AID164744; AID164928; AID164930; AID371442
Purine nucleoside phosphorylaseMus musculus (house mouse)Ki0.00000.00000.00000.0000AID164739
Purine nucleoside phosphorylase Bos taurus (cattle)Ki0.00000.00000.53072.7000AID1571175; AID164739
Purine nucleoside phosphorylasePlasmodium falciparum (malaria parasite P. falciparum)Ki0.00090.00050.00540.0290AID1578782
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
inosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
urate biosynthetic processPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of T cell proliferationPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of alpha-beta T cell differentiationPurine nucleoside phosphorylaseHomo sapiens (human)
allantoin metabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
nucleobase-containing compound metabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
inosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
deoxyinosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
deoxyadenosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
purine ribonucleoside salvagePurine nucleoside phosphorylaseHomo sapiens (human)
IMP catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
nicotinamide riboside catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
immune responsePurine nucleoside phosphorylaseHomo sapiens (human)
nucleotide biosynthetic processPurine nucleoside phosphorylaseHomo sapiens (human)
response to xenobiotic stimulusPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of interleukin-2 productionPurine nucleoside phosphorylaseHomo sapiens (human)
purine-containing compound salvagePurine nucleoside phosphorylaseHomo sapiens (human)
dAMP catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
purine ribonucleoside salvagePurine nucleoside phosphorylase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
nucleoside bindingPurine nucleoside phosphorylaseHomo sapiens (human)
purine nucleobase bindingPurine nucleoside phosphorylaseHomo sapiens (human)
purine-nucleoside phosphorylase activityPurine nucleoside phosphorylaseHomo sapiens (human)
protein bindingPurine nucleoside phosphorylaseHomo sapiens (human)
phosphate ion bindingPurine nucleoside phosphorylaseHomo sapiens (human)
identical protein bindingPurine nucleoside phosphorylaseHomo sapiens (human)
guanosine phosphorylase activityPurine nucleoside phosphorylaseHomo sapiens (human)
purine-nucleoside phosphorylase activityPurine nucleoside phosphorylase Bos taurus (cattle)
guanosine phosphorylase activityPurine nucleoside phosphorylase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionPurine nucleoside phosphorylaseHomo sapiens (human)
cytoplasmPurine nucleoside phosphorylaseHomo sapiens (human)
cytosolPurine nucleoside phosphorylaseHomo sapiens (human)
secretory granule lumenPurine nucleoside phosphorylaseHomo sapiens (human)
extracellular exosomePurine nucleoside phosphorylaseHomo sapiens (human)
ficolin-1-rich granule lumenPurine nucleoside phosphorylaseHomo sapiens (human)
cytoplasmPurine nucleoside phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID164930Equilibrium dissociation constant determined against human purine nucleoside phosphorylase (PNP) after slow-onset inhibition2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.
AID164928Inhibition of human purine nucleoside phosphorylase; Initial rate.2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.
AID1578784Inhibition of human PNP assessed as inhibitor constant for enzyme-inhibitor-substrate complex formation2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID164744Inhibitory activity of compound against human purine nucleoside phosphorylase (PNP)2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.
AID1571176Inhibition of human PNP using inosine as substrate by xanthine oxidase coupled assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
The transition to magic bullets - transition state analogue drug design.
AID164739Inhibitory activity of compound against bovine purine nucleoside phosphorylase (PNP)2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.
AID1578782Inhibition of Plasmodium falciparum His-tagged PNP assessed as inhibitor constant for enzyme-inhibitor-substrate complex formation2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID164741Binding affinity towards Human Purine Nucleoside Phosphorylase was reported2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase.
AID164604Rate constant of compound was determined for interaction with bovine purine nucleoside phosphorylase (PNP)2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.
AID164740Rate constant of compound was determined for interaction with human purine nucleoside phosphorylase (PNP)2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.
AID1578783Inhibition of human PNP assessed as inhibitor constant for enzyme-inhibitor complex formation2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID1571175Inhibition of bovine spleen PNP using inosine as substrate by xanthine oxidase coupled assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
The transition to magic bullets - transition state analogue drug design.
AID371442Inhibition of human PNP by xanthine-oxidase coupled assay2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase.
AID164742Dissociation constant against Human Purine Nucleoside Phosphorylase was reported2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase.
AID1578781Inhibition of Plasmodium falciparum His-tagged PNP assessed as inhibitor constant for enzyme-inhibitor complex formation2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (13.64)18.2507
2000's14 (63.64)29.6817
2010's5 (22.73)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (22.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (77.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]